HSCI Index Rebalance & Stock Connect: Inclusions & Exclusions
There are 36 inclusions/ 29 exclusions for the Hang Seng Composite Index. 9 stocks will be deleted from the Stock Connect Buy list & there are a...
483 Views
Zhaoke Ophthalmology: Bringing Focus to China
Zhaoke Ophthalmology is a pre-revenue pharmaceutical company specializing in ophthalmic drugs for China that has filed to list on the HKEX. Lee's...
439 Views
Innovent Biologics Placement - Momentum Is Very Strong but past Deals Have Been Mixed
Innovent Biologics Inc (1801 HK) is looking to raise about U$600m to fund its clinical trials and product licensing and possible M&A. This will be...
420 Views
BeiGene: Novartis Grabs Tislelizumab Rights
BeiGene's deal with Novartis for PD-1 tislelizumab validates its competitive position, and marks a rising trend of Chinese companies licensing...
263 Views
Ocumension Theraputics Placement - IPO Was Hot, Deal Should Be Supported Despite Lock-Up Expiry
Ocumension Therapeutics (1477 HK) aims to raise around US$103m to commercialize new products, fund clinical trials and develop new facilities.
273 Views